Mark Enyedy - 17 Jun 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc. (LOGC)

Role
Director
Signature
/s/ Andrea Paul, as Attorney-in-Fact
Issuer symbol
LOGC
Transactions as of
17 Jun 2022
Net transactions value
$0
Form type
4
Filing time
21 Jun 2022, 08:05:31 UTC
Previous filing
27 Dec 2022
Next filing
05 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Stock Option (right to buy) Award $0 +12,500 $0.000000 12,500 17 Jun 2022 Common Stock 12,500 $0.3800 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy.
F2 The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.